CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $602,000 | +309.5% | 193,500 | +344.8% | 0.01% | +300.0% |
| Q4 2021 | $147,000 | -79.3% | 43,500 | -55.7% | 0.00% | -81.2% |
| Q3 2020 | $711,000 | -59.0% | 98,224 | -80.3% | 0.02% | -54.3% |
| Q2 2020 | $1,736,000 | +658.1% | 497,524 | +221.0% | 0.04% | +600.0% |
| Q1 2020 | $229,000 | -57.9% | 155,000 | -44.2% | 0.01% | -28.6% |
| Q4 2019 | $544,000 | – | 277,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |